Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian...
Read more
Latest News
Category: Clinical
Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian...
Read more
Telix announces Phase II academic study of TLX66 in children with high-risk...
Read more
Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate...
Read more
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography...
Read more
Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder...
Read more
Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line...
Read more
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL...
Read more
Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product,...
Read more
Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced...
Read more
Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese...
Read more